Jim Hollingshead - ResMed Insider

ResMed -- USA Stock  

USD 101.17  2.37  2.40%

President - Americas

Dr. Jim Hollingshead, Ph.D. is President Sleep Business of the Company. Mr. Hollingshead joined ResMed in March 2010 as vice president of strategy and business development. In August 2011, his role was expanded to include the leadership of ResMed ventures and initiatives, the unit responsible for growing early stage businesses. In March 2013, he was appointed president Americas. Before joining us, Mr. Hollingshead spent 18 years in strategy consulting, where he worked with senior executives across a wide range of industries. From September 2008 to February 2010, he was a senior partner in the strategy and life sciences practices at Deloitte Consulting, based in San Francisco. Before that Mr. Hollingshead was managing partner, west coast for Monitor Group, a global strategy consulting firm. While at Monitor Group, Mr. Hollingshead worked in various offices around the world, and successfully launched and ran three different practices, including a panEuropean marketing strategy practice based in London
Age: 53  President Since 2017  Ph.D    
858-836-5000  http://www.resmed.com
Hollingshead holds an A.B. in history and international relations with highest distinction from Stanford University, and an M.A. and Ph.D in political science from the University of California at Berkeley, where he was awarded a graduate student fellowship by the National Science Foundation.

Management Efficiency

The company has Return on Asset of 9.1 % which means that on every $100 spent on asset it made $9.1 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.29 % implying that it generated $15.29 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 50.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 1.26 demonstrating that it may have difficulties to pay its financial commitments when the payables are due.

Similar Executives

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on New York Stock Exchange. It employs 6000 people.ResMed (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 6,000 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

ResMed Leadership Team

John Wareham, Director, MBA
Ronald Taylor, Director
Rob Douglas, President
Christopher Roberts, Director, MBA
Gary Pace, Director, Ph.D
Chris Roberts, Director, MBA
Robert Douglas, COO
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Brett Sandercock, CFO
Ron Taylor, Director
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA
Richard McHale, President
Donald Darkin, President

Stock Performance Indicators

Current Sentiment - RMD

ResMed Investor Sentiment
Greater number of Macroaxis users are at this time bullish on ResMed. What is your perspective on investing in ResMed? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Trending Equities

Currently Active Assets on Macroaxis
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago ago
Traded for 94.72
AOI   
 NYQ 
Purchased over 100 shares of
few hours ago ago
Traded for 24.75
REV   
 NYQ 
Purchased over 100 shares of
few hours ago ago
Traded for 22.75
FB   
 NMS 
Purchased few shares of
few hours ago ago
Traded for 166.69
VMW   
 NYQ 
Purchased over 20 shares of
few hours ago ago
Traded for 134.7
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago ago
Traded for 94.72
Additionally take a look at Your Equity Center. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.